Skip to main content
Top
Published in: Cancer Causes & Control 8/2014

01-08-2014 | Original paper

Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort

Authors: Karin Elebro, Salma Butt, Mozhgan Dorkhan, Helena Jernström, Signe Borgquist

Published in: Cancer Causes & Control | Issue 8/2014

Login to get access

Abstract

Purpose

Risk factors for breast cancer vary according to breast cancer subtype. This study analyzes the impact of potential risk factors in breast cancer by androgen receptor (AR) status.

Methods

A total of 17,035 women were followed in the population-based prospective Malmö Diet and Cancer Study. Baseline data included lifestyle factors including anthropometry, reproductive history, and exogenous hormone use. During follow-up (mean: 12.8 years), 747 invasive breast cancers were diagnosed. Expression of AR was determined by immunohistochemistry in tumor tissue microarrays.

Results

AR status was assessable in 516 of 747 tumors (69%). Among these, 467 tumors (90.5%) were AR positive (AR+) and 49 tumors (9.5%) were AR negative (AR-). AR negativity was significantly associated with estrogen receptor (ER) and progesterone receptor negativity, higher grade and proliferation (Ki67). Cox regression analyses stratified by AR status showed significant associations between reproductive factors and AR- breast cancer. The older the woman at first childbirth the higher the risk of AR- breast cancer; adjusted HR≤20yrs = 0.35, HR>20–≤25yrs = 0.62, HRnulliparous = 1.00, HR>25–≤30yrs = 1.29, HR>30yrs = 1.92, p trend = 0.001. No such association was seen for AR+ tumors. Similarly, ever oral contraceptive use increased the risk of AR- breast cancer [Adj. HR = 2.59, 95% CI (1.26–5.34)] compared to never use, but not for AR+ breast cancer.

Conclusions

Advanced age at first child birth and use of oral contraceptives were associated with increased risk of AR breast cancer. This study may contribute to enhanced understanding of the role of the AR in breast carcinogenesis and improve risk stratification tools for personalized breast cancer prevention.
Appendix
Available only for authorised users
Literature
1.
go back to reference Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res 13:1558–1568 Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res 13:1558–1568
2.
go back to reference Hickey TE, Robinson JL, Carroll JS, Tilley WD (2012) Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol (Baltimore, Md.) 26:1252–1267 Hickey TE, Robinson JL, Carroll JS, Tilley WD (2012) Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol (Baltimore, Md.) 26:1252–1267
3.
4.
go back to reference Hu R, Dawood S, Holmes MD et al (2011) Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res Off J Am Assoc Cancer Res 17:1867–1874CrossRef Hu R, Dawood S, Holmes MD et al (2011) Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res Off J Am Assoc Cancer Res 17:1867–1874CrossRef
5.
go back to reference Park S, Koo J, Park HS et al (2010) Expression of androgen receptors in primary breast cancer. Ann Oncol Off J Eur Soc Med Oncol/ESMO 21:488–492CrossRef Park S, Koo J, Park HS et al (2010) Expression of androgen receptors in primary breast cancer. Ann Oncol Off J Eur Soc Med Oncol/ESMO 21:488–492CrossRef
6.
go back to reference Peters AA, Buchanan G, Ricciardelli C et al (2009) Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 69:6131–6140PubMedCrossRef Peters AA, Buchanan G, Ricciardelli C et al (2009) Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 69:6131–6140PubMedCrossRef
7.
go back to reference Castellano I, Allia E, Accortanzo V et al (2010) Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 124:607–617PubMedCrossRef Castellano I, Allia E, Accortanzo V et al (2010) Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 124:607–617PubMedCrossRef
8.
go back to reference Park S, Koo JS, Kim MS et al (2011) Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol Off J Eur Soc Med Oncol/ESMO 22:1755–1762CrossRef Park S, Koo JS, Kim MS et al (2011) Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol Off J Eur Soc Med Oncol/ESMO 22:1755–1762CrossRef
9.
go back to reference Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ (1984) Androgen receptors in breast cancer. Cancer 54:2436–2440PubMedCrossRef Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ (1984) Androgen receptors in breast cancer. Cancer 54:2436–2440PubMedCrossRef
10.
go back to reference Park S, Park HS, Koo JS, Yang WI, Kim SI, Park BW (2012) Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers. Breast Cancer Res Treat 133:311–320PubMedCrossRef Park S, Park HS, Koo JS, Yang WI, Kim SI, Park BW (2012) Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers. Breast Cancer Res Treat 133:311–320PubMedCrossRef
11.
go back to reference Kuenen-Boumeester V, Van der Kwast TH, Claassen CC et al (1996) The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 32A:1560–1565PubMedCrossRef Kuenen-Boumeester V, Van der Kwast TH, Claassen CC et al (1996) The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 32A:1560–1565PubMedCrossRef
12.
go back to reference Ogawa Y, Hai E, Matsumoto K et al (2008) Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol. 13:431–435PubMedCrossRef Ogawa Y, Hai E, Matsumoto K et al (2008) Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol. 13:431–435PubMedCrossRef
13.
go back to reference Rizza P, Barone I, Zito D et al (2014) Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines. Breast Cancer Res 16:R21PubMedCentralPubMedCrossRef Rizza P, Barone I, Zito D et al (2014) Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines. Breast Cancer Res 16:R21PubMedCentralPubMedCrossRef
14.
go back to reference Garay JP, Karakas B, Abukhdeir AM et al (2012) The growth response to androgen receptor signaling in ERalpha-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res 14:R27PubMedCentralPubMedCrossRef Garay JP, Karakas B, Abukhdeir AM et al (2012) The growth response to androgen receptor signaling in ERalpha-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res 14:R27PubMedCentralPubMedCrossRef
15.
16.
go back to reference McNamara KM, Yoda T, Takagi K, Miki Y, Suzuki T, Sasano H (2013) Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol 133:66–76PubMedCrossRef McNamara KM, Yoda T, Takagi K, Miki Y, Suzuki T, Sasano H (2013) Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol 133:66–76PubMedCrossRef
17.
go back to reference Gucalp A, Tolaney S, Isakoff SJ et al (2013) Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 19:5505–5512 Gucalp A, Tolaney S, Isakoff SJ et al (2013) Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 19:5505–5512
18.
go back to reference Cochrane DR, Bernales S, Jacobsen BM et al (2014) Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res 16:R7PubMedCentralPubMedCrossRef Cochrane DR, Bernales S, Jacobsen BM et al (2014) Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res 16:R7PubMedCentralPubMedCrossRef
19.
go back to reference Birrell SN, Hall RE, Tilley WD (1998) Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia 3:95–103PubMedCrossRef Birrell SN, Hall RE, Tilley WD (1998) Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia 3:95–103PubMedCrossRef
20.
go back to reference Somboonporn W, Davis SR (2004) Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev 25:374–388PubMedCrossRef Somboonporn W, Davis SR (2004) Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev 25:374–388PubMedCrossRef
21.
go back to reference Labrie F, Luu-The V, Labrie C et al (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24:152–182PubMedCrossRef Labrie F, Luu-The V, Labrie C et al (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24:152–182PubMedCrossRef
22.
go back to reference Bernstein L, Ross RK (1993) Endogenous hormones and breast cancer risk. Epidemiol Rev 15:48–65PubMed Bernstein L, Ross RK (1993) Endogenous hormones and breast cancer risk. Epidemiol Rev 15:48–65PubMed
23.
go back to reference Jernstrom HC, Olsson H, Borg A (1997) Reduced testosterone, 17 beta-oestradiol and sexual hormone binding globulin, and increased insulin-like growth factor-1 concentrations, in healthy nulligravid women aged 19–25 years who were first and/or second degree relatives to breast cancer patients. Eur J Cancer Prev 6:330–340PubMedCrossRef Jernstrom HC, Olsson H, Borg A (1997) Reduced testosterone, 17 beta-oestradiol and sexual hormone binding globulin, and increased insulin-like growth factor-1 concentrations, in healthy nulligravid women aged 19–25 years who were first and/or second degree relatives to breast cancer patients. Eur J Cancer Prev 6:330–340PubMedCrossRef
24.
go back to reference Ma H, Bernstein L, Pike MC, Ursin G (2006) Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 8:R43PubMedCentralPubMedCrossRef Ma H, Bernstein L, Pike MC, Ursin G (2006) Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 8:R43PubMedCentralPubMedCrossRef
25.
go back to reference Berglund G, Elmstahl S, Janzon L, Larsson SA (1993) The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 233:45–51PubMedCrossRef Berglund G, Elmstahl S, Janzon L, Larsson SA (1993) The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 233:45–51PubMedCrossRef
26.
go back to reference World Health Organization (1982) Histological typing of breast tumors, 2nd edn. World Health Organization. Geneva, 1981. Ann Pathol 2:91–105 World Health Organization (1982) Histological typing of breast tumors, 2nd edn. World Health Organization. Geneva, 1981. Ann Pathol 2:91–105
27.
go back to reference Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef
28.
go back to reference Borgquist S, Anagnostaki L, Jirstrom K, Landberg G, Manjer J (2007) Breast tumours following combined hormone replacement therapy express favourable prognostic factors. Int J Cancer 120:2202–2207PubMedCrossRef Borgquist S, Anagnostaki L, Jirstrom K, Landberg G, Manjer J (2007) Breast tumours following combined hormone replacement therapy express favourable prognostic factors. Int J Cancer 120:2202–2207PubMedCrossRef
29.
go back to reference Dowsett M, Bartlett J, Ellis IO et al (2003) Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 199:418–423PubMedCrossRef Dowsett M, Bartlett J, Ellis IO et al (2003) Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 199:418–423PubMedCrossRef
30.
go back to reference World Health Organization (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 894:i–xii, 1–253 World Health Organization (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 894:i–xii, 1–253
31.
go back to reference World Health Organization W (2008) WHO expert consultation on waist circumference and waist-hip ratio. WHO World Health Organization W (2008) WHO expert consultation on waist circumference and waist-hip ratio. WHO
32.
go back to reference Molarius A, Seidell JC, Sans S, Tuomilehto J, Kuulasmaa K (1999) Waist and hip circumferences, and waist-hip ratio in 19 populations of the WHO MONICA Project. Int J Obes Relat Metab Disord J Int Assoc Study Obes 23:116–125CrossRef Molarius A, Seidell JC, Sans S, Tuomilehto J, Kuulasmaa K (1999) Waist and hip circumferences, and waist-hip ratio in 19 populations of the WHO MONICA Project. Int J Obes Relat Metab Disord J Int Assoc Study Obes 23:116–125CrossRef
33.
go back to reference Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM (2011) Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Modern Pathol Off J U S Can Acad Pathol Inc 24:924–931 Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM (2011) Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Modern Pathol Off J U S Can Acad Pathol Inc 24:924–931
35.
go back to reference Manjer J, Carlsson S, Elmstahl S et al (2001) The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 10:489–499PubMedCrossRef Manjer J, Carlsson S, Elmstahl S et al (2001) The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 10:489–499PubMedCrossRef
37.
go back to reference Parsa P, Parsa B (2009) Effects of reproductive factors on risk of breast cancer: a literature review. Asian Pacific J Cancer Prev APJCP 10:545–550 Parsa P, Parsa B (2009) Effects of reproductive factors on risk of breast cancer: a literature review. Asian Pacific J Cancer Prev APJCP 10:545–550
38.
go back to reference Wohlfahrt J, Mouridsen H, Andersen PK, Melbye M (1999) Reproductive risk factors for breast cancer by receptor status, histology, laterality and location. Int J Cancer 81:49–55PubMedCrossRef Wohlfahrt J, Mouridsen H, Andersen PK, Melbye M (1999) Reproductive risk factors for breast cancer by receptor status, histology, laterality and location. Int J Cancer 81:49–55PubMedCrossRef
39.
go back to reference Butt S, Borgquist S, Anagnostaki L, Landberg G, Manjer J (2009) Parity and age at first childbirth in relation to the risk of different breast cancer subgroups. Int J Cancer 125:1926–1934PubMedCrossRef Butt S, Borgquist S, Anagnostaki L, Landberg G, Manjer J (2009) Parity and age at first childbirth in relation to the risk of different breast cancer subgroups. Int J Cancer 125:1926–1934PubMedCrossRef
40.
go back to reference Martinez ME, Wertheim BC, Natarajan L et al (2013) Reproductive factors, heterogeneity, and breast tumor subtypes in women of Mexican descent. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res 22:1853–1861CrossRef Martinez ME, Wertheim BC, Natarajan L et al (2013) Reproductive factors, heterogeneity, and breast tumor subtypes in women of Mexican descent. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res 22:1853–1861CrossRef
41.
go back to reference Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713–1727 Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713–1727
42.
go back to reference Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059 Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059
43.
go back to reference Bao PP, Shu XO, Gao YT et al (2011) Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study. Am J Epidemiol 174:661–671PubMedCentralPubMedCrossRef Bao PP, Shu XO, Gao YT et al (2011) Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study. Am J Epidemiol 174:661–671PubMedCentralPubMedCrossRef
44.
go back to reference Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F (2008) Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 26:1260–1268CrossRef Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F (2008) Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 26:1260–1268CrossRef
46.
go back to reference Birrell SN, Butler LM, Harris JM, Buchanan G, Tilley WD (2007) Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J Off Publ Feder Am Soc Exp Biol 21:2285–2293 Birrell SN, Butler LM, Harris JM, Buchanan G, Tilley WD (2007) Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J Off Publ Feder Am Soc Exp Biol 21:2285–2293
47.
go back to reference Kandouz M, Lombet A, Perrot JY et al (1999) Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. J Steroid Biochem Mol Biol 69:463–471PubMedCrossRef Kandouz M, Lombet A, Perrot JY et al (1999) Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. J Steroid Biochem Mol Biol 69:463–471PubMedCrossRef
48.
go back to reference Lanzino M, De Amicis F, McPhaul MJ, Marsico S, Panno ML, Ando S (2005) Endogenous coactivator ARA70 interacts with estrogen receptor alpha (ERalpha) and modulates the functional ERalpha/androgen receptor interplay in MCF-7 cells. J Biol Chem 280:20421–20430PubMedCrossRef Lanzino M, De Amicis F, McPhaul MJ, Marsico S, Panno ML, Ando S (2005) Endogenous coactivator ARA70 interacts with estrogen receptor alpha (ERalpha) and modulates the functional ERalpha/androgen receptor interplay in MCF-7 cells. J Biol Chem 280:20421–20430PubMedCrossRef
49.
go back to reference Lundin KB, Henningson M, Hietala M, Ingvar C, Rose C, Jernstrom H (2011) Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients. Br J Cancer 105:1676–1683PubMedCentralPubMedCrossRef Lundin KB, Henningson M, Hietala M, Ingvar C, Rose C, Jernstrom H (2011) Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients. Br J Cancer 105:1676–1683PubMedCentralPubMedCrossRef
Metadata
Title
Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort
Authors
Karin Elebro
Salma Butt
Mozhgan Dorkhan
Helena Jernström
Signe Borgquist
Publication date
01-08-2014
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 8/2014
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-014-0394-2

Other articles of this Issue 8/2014

Cancer Causes & Control 8/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine